Cargando…

Palmitate-induced Regulation of PPARγ via PGC1α: a Mechanism for Lipid Accumulation in the Liver in Nonalcoholic Fatty Liver Disease

The aim was to examine the effect of free fatty acids on the regulation of PPARγ-PGC1α pathway, and the effect of PPARγ/PGC1α in NAFLD. The mRNA and protein expression of PGC1α and phospho/total PPARγ were examined in Huh7 cells after the palmitate/oleate treatment with/without the transfection with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maruyama, Hitoshi, Kiyono, Soichiro, Kondo, Takayuki, Sekimoto, Tadashi, Yokosuka, Osamu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4773281/ https://www.ncbi.nlm.nih.gov/pubmed/26941577 http://dx.doi.org/10.7150/ijms.13581

Ejemplares similares

Linoleate appears to protect against palmitate-induced inflammation in Huh7 cells
por: Maruyama, Hitoshi, et al.
Publicado: (2014)

Differential Clinical Impact of Ascites in Cirrhosis and Idiopathic Portal Hypertension
por: Maruyama, Hitoshi, et al.
Publicado: (2015)

Update on Pparγ and Nonalcoholic Fatty Liver Disease
por: Ables, Gene P.
Publicado: (2012)

Free fatty acid-based low-impedance liver image: a characteristic appearance in nonalcoholic steatohepatitis (NASH)
por: Maruyama, Hitoshi, et al.
Publicado: (2020)

Interrelationship between insulin resistance and portal haemodynamic abnormality in cirrhosis
por: Maruyama, Hitoshi, et al.
Publicado: (2017)

Intervening TNF-α via PPARγ with Gegenqinlian Decoction in Experimental Nonalcoholic Fatty Liver Disease
por: Wang, Yun-liang, et al.
Publicado: (2015)

Aspirin Improves Nonalcoholic Fatty Liver Disease and Atherosclerosis through Regulation of the PPARδ-AMPK-PGC-1α Pathway in Dyslipidemic Conditions
por: Han, Yoon-Mi, et al.
Publicado: (2020)

PPARγ and PGC-1α as Therapeutic Targets in Parkinson’s
por: Corona, Juan Carlos, et al.
Publicado: (2014)

Regulation of PPAR-γ activity in lipid-laden hepatocytes affects macrophage polarization and inflammation in nonalcoholic fatty liver disease
por: Li, Xiao-Yun, et al.
Publicado: (2022)

Palmitate-induced lipotoxicity is crucial for the pathogenesis of nonalcoholic fatty liver disease in cooperation with gut-derived endotoxin
por: Ogawa, Yuji, et al.
Publicado: (2018)

Role of Apolipoprotein A1 in PPAR Signaling Pathway for Nonalcoholic Fatty Liver Disease
por: Chen, Changxi, et al.
Publicado: (2022)

Elucidation of SIRT-1/PGC-1α-associated mitochondrial dysfunction and autophagy in nonalcoholic fatty liver disease
por: Jiang, Yan, et al.
Publicado: (2021)

The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease
por: Kumar, Divya P., et al.
Publicado: (2020)

PPARs and Liver Disease
por: Kondo, Yasuteru, et al.
Publicado: (2013)

Lanzhang Granules Ameliorate Nonalcoholic Fatty Liver Disease by Regulating the PPARα Signaling Pathway
por: Huang, Ping, et al.
Publicado: (2022)

The Effects of PPAR Agonists on Atherosclerosis and Nonalcoholic Fatty Liver Disease in ApoE(−/−)FXR(−/−) Mice
por: Lee, Yenna, et al.
Publicado: (2021)

PPARγ contributes to PKM2 and HK2 expression in fatty liver
por: Panasyuk, Ganna, et al.
Publicado: (2012)

Establishment of an Adult Medaka Fatty Liver Model by Administration of a Gubra-Amylin-Nonalcoholic Steatohepatitis Diet Containing High Levels of Palmitic Acid and Fructose
por: Fujisawa, Koichi, et al.
Publicado: (2021)

Modes-of-Action Related to Repeated Dose Toxicity: Tissue-Specific Biological Roles of PPARγ Ligand-Dependent Dysregulation in Nonalcoholic Fatty Liver Disease
por: Al Sharif, Merilin, et al.
Publicado: (2014)

Co-exposure to multi-walled carbon nanotube and lead ions aggravates hepatotoxicity of nonalcoholic fatty liver via inhibiting AMPK/PPARγ pathway
por: Liu, Enqin, et al.
Publicado: (2020)

Rab2A regulates the progression of nonalcoholic fatty liver disease downstream of AMPK-TBC1D1 axis by stabilizing PPARγ
por: Chen, Zi-Yue, et al.
Publicado: (2022)

Swimming exercise ameliorates insulin resistance and nonalcoholic fatty liver by negatively regulating PPARγ transcriptional network in mice fed high fat diet
por: Zhang, Yong, et al.
Publicado: (2023)

Murine Models of Nonalcoholic Fatty Liver Disease and Steatohepatitis
por: Ninomiya, Masashi, et al.
Publicado: (2012)

Attenuation of Immune-Mediated Renal Injury by Telmisartan, an Angiotensin Receptor Blocker and a Selective PPAR-γ Activator
por: Hamano, Yuki, et al.
Publicado: (2011)

Misregulation of PPAR Functioning and Its Pathogenic Consequences Associated with Nonalcoholic Fatty Liver Disease in Human Obesity
por: Videla, Luis A., et al.
Publicado: (2012)

Fimasartan Ameliorates Nonalcoholic Fatty Liver Disease through PPARδ Regulation in Hyperlipidemic and Hypertensive Conditions
por: Lee, Yong-Jik, et al.
Publicado: (2017)

Sijunzi, Lizhong, and Fuzilizhong Decoction Alleviate Nonalcoholic Fatty Liver Disease through Activation of PPAR Pathway
por: Yang, Jiayao, et al.
Publicado: (2020)

Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis †
por: Yamashita, Shizuya, et al.
Publicado: (2023)

Liver fibrosis is associated with carotid atherosclerosis in patients with liver biopsy-proven nonalcoholic fatty liver disease
por: Arai, Taeang, et al.
Publicado: (2021)

Nonalcoholic Fatty Liver Disease
por: Filipović, Branka, et al.
Publicado: (2018)

Nonalcoholic fatty liver disease
por: Bebawi, Emmanuel, et al.
Publicado: (2023)

Therapeutic potential of PPARγ natural agonists in liver diseases
por: Wu, Liwei, et al.
Publicado: (2020)

Ectopic Fat Accumulation and Distant Organ-Specific Insulin Resistance in Japanese People with Nonalcoholic Fatty Liver Disease
por: Kato, Ken-ichiro, et al.
Publicado: (2014)

PGC-1α Protects against Hepatic Ischemia Reperfusion Injury by Activating PPARα and PPARγ and Regulating ROS Production
por: Wang, Chaoqun, et al.
Publicado: (2021)

Lipid accumulation product is a predictor of nonalcoholic fatty liver disease in childhood obesity
por: Özcabı, Bahar, et al.
Publicado: (2019)

LY6D is crucial for lipid accumulation and inflammation in nonalcoholic fatty liver disease
por: Lee, Jibeom, et al.
Publicado: (2023)

Current Clinical Trial Status and Future Prospects of PPAR-Targeted Drugs for Treating Nonalcoholic Fatty Liver Disease
por: Kamata, Shotaro, et al.
Publicado: (2023)

Lack of Genetic Associations of PPAR-γ and PGC-1α with Alzheimer's Disease and Parkinson's Disease with Dementia
por: Shibata, Nobuto, et al.
Publicado: (2013)

Circulating Citrate Is Associated with Liver Fibrosis in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
por: Amjad, Waseem, et al.
Publicado: (2023)

Nonalcoholic fatty liver disease stratification by liver lipidomics
por: Vvedenskaya, Olga, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_eejckciljdvu1knd8j1hsj31pt